Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine (CLASS-D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04206059
Recruitment Status : Not yet recruiting
First Posted : December 20, 2019
Last Update Posted : May 13, 2020
Sponsor:
Information provided by (Responsible Party):
Ben Palanca, Washington University School of Medicine

Brief Summary:
Prospective within-subject study of dexmedetomidine sedation paired with CLAS conditions in repeated blocks. Intervention will consist of CLAS in-phase with EEG slow waves. Anti-phase stimulation will serve as an active control while sham stimulation will serve as a passive control.

Condition or disease Intervention/treatment Phase
Sleep Sedation Complication Radiation: MRI Diagnostic Test: Quantitative Sensory Testing (QST) Diagnostic Test: Home sleep study Other: Acoustic stimulation (65db) up-slope of EEG with QST Other: Acoustic stimulation (65db) down-slope of EEG with QST Other: 0 db with QST Drug: Dexmedetomidine Not Applicable

Detailed Description:
Both nonpharmacologic and pharmacologic interventions augment expression of EEG slow waves that mimic those of natural sleep. Closed loop auditory stimulation (CLAS) is a noninvasive inexpensive approach to augment the spectral power and duration of these slow waves. Whether in-phase CLAS may address this need is unknown, since acoustic potentiation of pharmacologically-induced slow waves has not been investigated. This prospective within-subject study of dexmedetomidine sedation paired with CLAS will assess the feasibility of augmenting EEG slow waves during sedation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine
Estimated Study Start Date : August 1, 2020
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : January 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CLASS-D Cohort
Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated trough of EEG slow wave oscillation, and 0 dB stimulation.
Radiation: MRI
A non-contrast brain MRI will be acquired for localizing EEG slow waves
Other Name: Structural magnetic resonance imaging

Diagnostic Test: Quantitative Sensory Testing (QST)
Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
Other Name: Quantitative Sensory Testing

Diagnostic Test: Home sleep study
Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
Other Name: Unattended polysomnography

Other: Acoustic stimulation (65db) up-slope of EEG with QST
Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
Other Name: In-phase CLAS with sensory testing

Other: Acoustic stimulation (65db) down-slope of EEG with QST
65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
Other Name: Anti-phase CLAS with sensory testing

Other: 0 db with QST
sham stimulation (0 dB volume)
Other Name: Sham CLAS with sensory testing

Drug: Dexmedetomidine
All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
Other Name: Dexmedetomidine hydrochloride




Primary Outcome Measures :
  1. Difference in EEG slow wave amplitude from sham to in-phase stimulation [ Time Frame: up to 3 months after consent ]
    EEG slow waves amplitude relative to the timing of the stimulation

  2. Difference in EEG slow wave duration from sham to in-phase stimulation [ Time Frame: up to 3 months after consent ]
    EEG slow waves duration relative to the timing of the stimulation

  3. Difference in EEG slow wave amplitude from anti-phase to in-phase stimulation [ Time Frame: up to 3 months after consent ]
    EEG slow waves amplitude relative to the timing of the stimulation

  4. Difference in EEG slow wave duration from anti-phase to in-phase stimulation [ Time Frame: up to 3 months after consent ]
    EEG slow waves duration relative to the timing of the stimulation


Secondary Outcome Measures :
  1. Difference of reactivity to thermal stimulation from anti-phase to in-phase stimulation [ Time Frame: up to 3 months after consent ]
    Threshold for responsiveness to thermal stimulation

  2. Difference of reactivity to thermal stimulation from sham to in-phase stimulation [ Time Frame: up to 3 months after consent ]
    Threshold for responsiveness to thermal stimulation

  3. Change in slow wave activity on the night of the intervention will be compared to that on the night prior to the study session. [ Time Frame: up to 3 months after consent ]
    Slow wave activity calculated during N3 sleep

  4. Localization of slow waves [ Time Frame: up to 3 months after consent ]
    Brain regions with localization of EEG slow waves during dexmedetomidine sedation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18-40 years
  • Healthy volunteers (American Society of Anesthesiologists Physical Status 1-2).

Exclusion Criteria:

  • Diagnosed sleep disorders
  • Habitually short sleepers
  • Diagnosed psychiatric disorders
  • Use of psychoactive medication (e.g., antidepressants, mood stabilizers or antipsychotics), diagnosed hearing disorder
  • Neck circumference > 40 cm
  • Body Mass Index > 30
  • Acknowledged recreational drug or nicotine use
  • Resting heart rate during slow wave sleep < 40 beats per minute
  • Pregnancy or nursing
  • Persistently inconsistent or elevated QST heat pain tolerance thresholds (>50 ºC).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04206059


Contacts
Layout table for location contacts
Contact: Christian Guay, MD 314-599-2922 cguay@wustl.edu

Sponsors and Collaborators
Washington University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Ben J Palanca, MD PhD Washington University School of Medicine
Publications:
Layout table for additonal information
Responsible Party: Ben Palanca, Assistant Professor, Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT04206059    
Other Study ID Numbers: 201907086
First Posted: December 20, 2019    Key Record Dates
Last Update Posted: May 13, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Dexmedetomidine
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action